M1 Kliniken AG Maintains Strong Performance in Q3

First Berlin Equity Research GmbH has reaffirmed its "Buy" recommendation for M1 Kliniken AG, citing the company's solid performance in the third quarter of 2024. Analyst Ellis Acklin maintains a target price of €28, highlighting the contribution of M1 Kliniken's Beauty segment to its overall earnings growth.

Despite a stable group turnover that closely matched forecasts, the Beauty segment saw an impressive 41% year-on-year growth in EBIT. This growth drove operating income to surpass estimates by 9%. Meanwhile, the Trade segment reported a consistent EBIT margin of 2% with a turnover of €67 million for the September quarter.

M1 Kliniken expanded its healthcare reach by opening new centers, bringing the total to 63, including new locations in Germany and Austria. The updated 2024 performance expectations reflect the company's outperformance in the first nine months of the year, reinforcing the positive outlook shared by First Berlin Equity Research.